The Special Investment Facilitation Council’s (SIFC) proactive strategy is driving innovation and investment in Pakistan’s pharmaceutical industry.

In a statement, the Pakistan Pharmaceutical Manufacturers Association (PPMA) expressed gratitude to the SIFC for its support in recent amendments to the Drugs Act.

According to PPMA, the amendments will help align Pakistan’s regulatory framework with international standards, paving the way for improved compliance and greater investor confidence.

The reforms are expected to ensure uninterrupted availability of essential medicines while also enhancing the production of advanced drugs. Officials anticipate a rise in foreign investment in the country’s pharmaceutical sector as a result of these measures.